WO2000077190A3 - Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt - Google Patents

Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt Download PDF

Info

Publication number
WO2000077190A3
WO2000077190A3 PCT/US2000/015098 US0015098W WO0077190A3 WO 2000077190 A3 WO2000077190 A3 WO 2000077190A3 US 0015098 W US0015098 W US 0015098W WO 0077190 A3 WO0077190 A3 WO 0077190A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
serine
induction
growth factor
protein kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/015098
Other languages
French (fr)
Other versions
WO2000077190A2 (en
Inventor
Kun Guo
Yuri Ivashchenko
Kenneth Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ516054A priority Critical patent/NZ516054A/en
Priority to KR1020017015908A priority patent/KR20020012270A/en
Priority to CA002376630A priority patent/CA2376630A1/en
Priority to JP2001503635A priority patent/JP2003530818A/en
Priority to AU51758/00A priority patent/AU773450B2/en
Priority to EP00936443A priority patent/EP1187911A2/en
Priority to SI200020029A priority patent/SI20978A/en
Priority to BR0011503-7A priority patent/BR0011503A/en
Priority to HK02103080.3A priority patent/HK1041500A1/en
Priority to IL14673000A priority patent/IL146730A0/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Priority to MXPA01012748A priority patent/MXPA01012748A/en
Publication of WO2000077190A2 publication Critical patent/WO2000077190A2/en
Publication of WO2000077190A3 publication Critical patent/WO2000077190A3/en
Priority to NO20016025A priority patent/NO20016025L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods and compositions for therapeutic angiogenesis. More especially, this invention is directed to induction of vascular endothelial growth factor (VEGF) expression by the serine/threonine protein kinase AKT. Preferably, the compositions and methods according to the invention comprise a nucleic acid encoding AKT, and administration thereof.
PCT/US2000/015098 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt Ceased WO2000077190A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
HK02103080.3A HK1041500A1 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
CA002376630A CA2376630A1 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
JP2001503635A JP2003530818A (en) 1999-06-11 2000-06-01 Introduction of vascular endothelial growth factor (VEGF) by serine / threonine protein kinase Akt
AU51758/00A AU773450B2 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (VEGF) by the serine/threonine protein kinase AKT
EP00936443A EP1187911A2 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
SI200020029A SI20978A (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
BR0011503-7A BR0011503A (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vdgf) by serine protein / threonine kinase akt
NZ516054A NZ516054A (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (VEGF) by the serine/threonine protein kinase AKT
KR1020017015908A KR20020012270A (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor(VEGF) by the serine/threonine protein kinase AKT
IL14673000A IL146730A0 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
MXPA01012748A MXPA01012748A (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt.
NO20016025A NO20016025L (en) 1999-06-11 2001-12-10 Induction of Vascular Endothelial Growth Factor (VEGF) by Serine / Threonine Protein Kinase Akt

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13872499P 1999-06-11 1999-06-11
US60/138,724 1999-06-11
GB9926058.0 1999-11-03
GB9926058 1999-11-03

Publications (2)

Publication Number Publication Date
WO2000077190A2 WO2000077190A2 (en) 2000-12-21
WO2000077190A3 true WO2000077190A3 (en) 2001-04-12

Family

ID=26316052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015098 Ceased WO2000077190A2 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Country Status (17)

Country Link
EP (1) EP1187911A2 (en)
JP (1) JP2003530818A (en)
KR (1) KR20020012270A (en)
CN (1) CN1360629A (en)
AU (1) AU773450B2 (en)
BR (1) BR0011503A (en)
CA (1) CA2376630A1 (en)
CZ (1) CZ20014444A3 (en)
HK (1) HK1041500A1 (en)
HU (1) HUP0201663A3 (en)
IL (1) IL146730A0 (en)
MX (1) MXPA01012748A (en)
NO (1) NO20016025L (en)
NZ (1) NZ516054A (en)
PL (1) PL352859A1 (en)
SI (1) SI20978A (en)
WO (1) WO2000077190A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE402995T1 (en) * 1999-03-19 2008-08-15 Aventis Pharma Inc ACT-3 NUCLEIC ACID, POLYPEPTIDES AND THEIR USE
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
MXPA01010459A (en) 1999-04-16 2003-08-20 Univ Yale eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING.
US6187586B1 (en) * 1999-12-29 2001-02-13 Isis Pharmaceuticals, Inc. Antisense modulation of AKT-3 expression
ATE284701T1 (en) * 2000-03-02 2005-01-15 Ludwig Inst Cancer Res METHOD FOR TREATING TUMORS WHICH EXPRESS THE VASCULAR ENDOTHELIAL GROWTH FACTOR D
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056866A2 (en) * 1999-03-19 2000-09-28 Aventis Pharmaceuticals Products Inc. Akt-3 nucleic acids, polypeptides, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056866A2 (en) * 1999-03-19 2000-09-28 Aventis Pharmaceuticals Products Inc. Akt-3 nucleic acids, polypeptides, and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHENG J Q ET AL: "AKT2, A PUTATIVE ONCOGENE ENCODING A MEMBER OF A SUBFAMILY OF PROTEIN-SERINA/THREONINE KINASES, IS AMPLIFIED IN HUMAN OVARIAN CARCINOMAS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 89, 1989, pages 9267 - 9271, XP000917044, ISSN: 0027-8424 *
FUJIO YASUSHI ET AL: "Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 23, 4 June 1999 (1999-06-04), pages 16349 - 16354, XP002155565, ISSN: 0021-9258 *
GERBER HANS-PETER ET AL: "Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: Requirement for Flk-1/KDR activation.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 46, 13 November 1998 (1998-11-13), pages 30336 - 30343, XP002155564, ISSN: 0021-9258 *
JIANG BING-HUA ET AL: "Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 4, 15 February 2000 (2000-02-15), Feb. 15, 2000, pages 1749 - 1753, XP002155566, ISSN: 0027-8424 *
NAKATANI KANAME ET AL: "Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,ACADEMIC PRESS INC. ORLANDO, FL,US, vol. 257, no. 3, 21 April 1999 (1999-04-21), pages 906 - 910, XP002153015, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2000077190A2 (en) 2000-12-21
NO20016025L (en) 2002-02-08
JP2003530818A (en) 2003-10-21
NZ516054A (en) 2004-04-30
NO20016025D0 (en) 2001-12-10
PL352859A1 (en) 2003-09-08
AU5175800A (en) 2001-01-02
AU773450B2 (en) 2004-05-27
KR20020012270A (en) 2002-02-15
CZ20014444A3 (en) 2002-05-15
EP1187911A2 (en) 2002-03-20
IL146730A0 (en) 2002-07-25
MXPA01012748A (en) 2002-07-02
HK1041500A1 (en) 2002-07-12
HUP0201663A2 (en) 2002-08-28
HUP0201663A3 (en) 2005-01-28
SI20978A (en) 2003-02-28
CN1360629A (en) 2002-07-24
BR0011503A (en) 2002-03-05
CA2376630A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
WO2002008186A3 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
HUP0003386A3 (en) Use of crf antagonists for the preparation of pharmaceutical compositions treating depression, cardiovascular diseases
WO2003022227A3 (en) Antisense modulation of vascular endothelial growth factor receptor-1 expression
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
WO2002014314A3 (en) Substituted pyrazoles
WO2002014315A3 (en) Substituted pyrazoles
WO2003053349A3 (en) Inhibitors of hepatitis c virus
WO2002014317A3 (en) Substituted pyrazoles
WO2002017914A8 (en) Fused pyrrolocarbazoles against inflammation
WO1999054326A8 (en) Dihydropyrimidines
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
BR0116047A (en) Heterocyclic Ether Substituted Imidazoquinolines
WO2000073469A3 (en) Protein kinases
WO2004043383A8 (en) A new target for angiogenesis and anti-angiogenesis therapy
ZA200404475B (en) Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof.
WO2005063764A3 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
HK1041500A1 (en) Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
WO2003057149A3 (en) 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
WO2003051838A3 (en) Protein kinase inhibitors
AU7525398A (en) Inhibitors for urokinase receptor
WO2001049325A3 (en) Gene therapy to promote angiogenesis and/or the treatment of heart failure
WO2002058718A3 (en) Use of compositions containing pdgf-bb for promoting angiogenesis
WO2002060382A3 (en) Novel compounds and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000936443

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/09709

Country of ref document: ZA

Ref document number: 200109709

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1712/CHE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2376630

Country of ref document: CA

Ref document number: 2376630

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2001 503635

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/012748

Country of ref document: MX

Ref document number: 1020017015908

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2001-4444

Country of ref document: CZ

Ref document number: 516054

Country of ref document: NZ

Ref document number: 51758/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200020029

Country of ref document: SI

Ref document number: 00810249X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020017015908

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000936443

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-4444

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 51758/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020017015908

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000936443

Country of ref document: EP